基本信息
views: 0
Career Trajectory
Bio
1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care
Accomplishments
1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.
Research Interests
Papers共 343 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Endocrine Practiceno. 5 (2024): S65-S66
Journal of Clinical Oncologyno. 16_suppl (2024): 11141-11141
James Isaacs,Afreen Idris Shariff,Jeffrey Crawford,Michel Khouri,Meenal Kheterpal,Sarah Sammons, Michelle Nelson Ferreira, April Wall, Jane E. Onken, Lindsay King,Suma Shah,David I. Ortiz-Melo,
Side Effects of Cancer Therapypp.1-92, (2024)
Journal of Clinical Oncologyno. 16_suppl (2024)
Endocrine Practiceno. 5 (2024): S65
Journal of cachexia, sarcopenia and muscleno. 3 (2024): 1054-1061
Cancer Treatment and Research Communications (2024): 100824-100824
Load More
Author Statistics
#Papers: 341
#Citation: 16761
H-Index: 59
G-Index: 125
Sociability: 7
Diversity: 0
Activity: 2
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn